3LEGS RESOURCES PLC Inactive Instrument
3Legs Resources plc Share Price London S.E.
Equities
IM00B52P5P72
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - GBX | - |
|
| 2019 | SalvaRx Evaluates Takeover Opportunities | CI |
| 2019 | Salvarx Group plc Reports Earnings Results for the Half Year Ended June 30, 2019 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2017 | - | Sales 2018 | - | Capitalization | 2.85Cr 238.15Cr |
|---|---|---|---|---|---|
| Net income 2017 | -10L -8.35Cr | Net income 2018 | - 0 | EV / Sales 2017 | - |
| Net Debt 2017 | 22.22L 19Cr | Net Debt 2018 | 8L 6.37Cr | EV / Sales 2018 | - |
| P/E ratio 2017 |
-4.13
x | P/E ratio 2018 |
83
x | Employees | - |
| Yield 2017 * |
-
| Yield 2018 |
-
| Free-Float | 20.33% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Denham Eke
DFI | Director of Finance/CFO | 73 | 08/19/08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jim Mellon
CHM | Chairman | 68 | - |
Peter Redmond
BRD | Director/Board Member | 76 | - |
Gregory Bailey
FOU | Founder | 68 | 01/07/01 |
- SalvaRx Group Plc is a Isle of Man-based company. The Company engaged in drug discovery and development, focused on immune oncology. The Company invests in novel cancer immuno-therapies and provides its portfolio companies with operational support ranging from direct operation of subsidiaries to advisory or part-time involvement in more established companies.
| 1st Jan change | Capi. | |
|---|---|---|
| +8.29% | 11TCr | |
| +10.21% | 11TCr | |
| +0.41% | 2.23TCr | |
| -11.90% | 2.22TCr | |
| -5.99% | 1.94TCr | |
| -37.36% | 1.79TCr | |
| -5.17% | 1.72TCr | |
| +7.70% | 1.43TCr | |
| +37.65% | 1.25TCr |
